Brief: Bavarian Nordic Maintains 2025 Outlook
09/05/2025 06:45
May 9 (Reuters) - Bavarian Nordic A/S BAVA.CO: OUTLOOK FY REVENUE DKK 5,700-6,700 MILLION Q1 EBITDA DKK 420 MILLION Q1 REVENUE DKK 1,347 MILLION ON CHIKUNGUNYA VACCINE: WE ALSO RECORDED OUR FIRST US SALES OF CHIKUNGUNYA VACCINE AFTER ITS APPROVAL IN FEBRUARY AND AHEAD OF APRIL RECOMMENDATION FROM ACIP ON CHIKUNGUNYA VACCINE: OUR PHASED LAUNCH PLAN FOR THE VACCINE IS PROGRESSING AS PLANNED Source text: ID:nGNE5wDdQ6 Further company coverage: BAVA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract
Brief: Bavarian Nordic Secures Additional Government Contract For The Supply Of Smallpox/Mpox Vaccine
Brief: Bavarian Nordic Launches Final Tranche Of Buy-Back Program
Bavarian Nordic falls as high costs, lower vaccine sales hit Q1 results
Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline